SecProbe.io

CORRESP
1
filename1.htm

VIA EDGAR

April 17, 2024

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Trade & Services

Washington, D.C. 20549

    Attention:
    Ms. Tamika Sheppard and Ms. Laura Crotty

Re: Pysence Biomedical Ltd.

Registration Statement on Form F-1

Filed February 9, 2024

File No. 333-276973

Dear Ms. Sheppard and Ms. Crotty:

Pysence Biomedical Ltd. (the
 “Company”) hereby transmits its response to the comment letter received from the staff (the “Staff”)
of the U.S. Securities and Exchange Commission (the “Commission”) on February 23, 2024, relating to the Registration
Statement on Form F-1, submitted by the Company to the Commission on February 9, 2024 (the “Registration Statement”).
All page references in the responses set forth below refer to page numbers in the Amendment No. 1 to the Registration Statement (“Amendment
No. 1”).

For the Staff’s convenience,
we have repeated below the Staff’s comments in bold and have followed each comment with the Company’s response.

Registration Statement on Form F-1 filed February 9, 2024

Prospectus Cover Page, page 1

 1. Please revise the cover page to disclose the total shares
redeemed in connection with the business combination, expressed as a percentage. Please also disclose the balance remaining in the Trust
Account as a result of the redemptions, that the Minimum Cash Condition and PIPE Investment Conditions were both waived in order to close
the business combination, and that the company did not secure a PIPE in relation to the transaction, if true.

In response to the Staff’s comment,
the Company has revised the disclosure on the cover page and page 1 of Amendment No. 1.

 2. Please revise the cover page to disclose 1) the effective
price of the 18,750,000 common shares issued pursuant to the First Tranche Notes, and 2) the "nominal fee" paid for the 3,000,000
Founder Shares.

      1

In response to the Staff’s comment,
the Company has revised the disclosure on the cover page and page 2 of Amendment No. 1.

 3. We note the significant number of redemptions of your common
stock in connection with the business combination and that as of the closing of the business combination on January 25, 2024, a total
of 13,390,659 shares of common stock were outstanding, only 119,659 of which were held by public shareholders. As such, the 22,496,000
shares being registered for resale constitute vastly more than the company's public float and total shares outstanding. We also note
a substantial majority of the shares being registered for resale may have been purchased by the Investors and the Sponsor for prices
considerably below the current market price of the common stock. Revise your disclosure to reflect these facts and highlight the significant
negative impact sales of shares pursuant to this registration statement could have on the public trading price of the common stock.

In response to the Staff’s comment,
the Company has revised the disclosure on the cover page, page 7 and page 39 of Amendment No. 1.

 4. Please clarify whether the 18,750,000 shares being offered
by the Investors in relation to the First Tranche Notes include the 1,300,000 Structuring Shares issued at the initial closing of the
financing and concurrently with the closing of the business combination.

In response to the Staff’s comment,
the Company has revised the disclosure on the cover page and page 2 of Amendment No. 1.

Prospectus Summary, page 6

 5. Please expand your discussion here to reflect the fact that
this offering involves the potential sale of more than the company's total outstanding shares for resale and discuss how such sales could
impact the market price of the company’s common stock.

In response to the Staff’s comment,
the Company has revised the disclosure on the cover page and page 7 of Amendment No. 1.

Securities Purchase Agreement, page 8

 6. We note your disclosure regarding the Conversion Price adjustments
included in the First Tranche Notes. Please revise this disclosure to include a discussion of the material terms and reset dates related
to such adjustments.

In response to the Staff’s comment,
the Company has revised the disclosure on page 9 of Amendment No. 1.

 7. We note your discussion of the inducement in the form of
Structuring Shares given to the Investors in exchange for entering into the Securities Purchase Agreement and the Notes, which states
that the remaining 1,700,000 Structuring Shares to be paid are subject to the terms of Call Option Agreements, by and among the Investors
and certain members of the Sponsor. Please revise your disclosure to describe the material terms of the Call Option Agreements and file
a copy as an exhibit to the registration statement.

      2

In response to the Staff’s comment,
the Company has revised the disclosure on page 9 of Amendment No. 1 and have filed the form of Call Option Agreement as Exhibit 10.17
to Amendment No. 1.

Risk Factors, page 17

 8. Include an additional risk factor highlighting the negative
pressure potential sales of shares pursuant to this registration statement could have on the public trading price of the common shares.
To illustrate this risk, disclose the purchase price of the securities being registered for resale and the percentage that these shares
currently represent of the total number of shares outstanding. Also disclose that even though the current trading price is significantly
below the SPAC IPO price, the private investors have an incentive to sell because they will still profit on sales because of the lower
price at which they purchased their shares compared to the public investors.

In response to the Staff’s comment,
the Company has revised the disclosure on page 39 of Amendment No. 1.

 9. Please include a risk factor disclosing the dilution risks
associated with the outstanding Private Warrants. In this risk factor, quantify the number of shares that may be issued upon exercise
of the Private Warrants and disclose the exercise price compared to the market price of the underlying securities. In relation to the
number of shares that may be issued upon exercise, please contrast this figure with the total number of shares outstanding as of the
closing of the business combination.

In response to the Staff’s comment,
the Company has revised the disclosure on page 41 of Amendment No. 1.

 10. You state on page 35 that you "expect" that your
shares will be listed on Nasdaq, and that as a result such securities will be covered securities. Please revise to update this disclosure,
as the company's common shares and warrants are now listed on Nasdaq.

In response to the Staff’s comment,
the Company has revised the disclosure on page 40 of Amendment No. 1.

Management's
Discussion and Analysis of Financial Conditions and Results of Operations

Liquidity and Capital Resources, page 47

 11. We note your statement on page 17 that you expect that the
proceeds from the business combination as well as existing cash will be sufficient to fund operations for 18 months. However, in your
Form F-4/A filed November 13, 2023, you projected that the combined company would require an estimated $13.4 million for the first 12
months following the closing of the transaction. We also note that both the Minimum Cash Condition and PIPE Investment Condition were
waived at closing and that post-redemptions the Trust Account contained only $1.38 million. Please revise your Liquidity and Capital
Resources discussion to address the above and provide further information regarding how the company believes that the proceeds and its
existing cash is sufficient to fund operations for the next 18 months. If the company is likely to have to seek additional capital, discuss
the effect of this offering on the company’s ability to raise additional capital.

      3

In response to the Staff’s comment,
the Company has revised the disclosure on pages 21 and 58 of Amendment No. 1.

Unaudited Pro Forma Condensed Combined Financial Information

Note 6 - Net Earnings (Loss) per Share, page 64

 12. We note that the unaudited pro forma condensed combined financial
information was prepared to provide an understanding of the company upon consummation of the business combination for illustrative purposes.
We also note the table in Note 6 which sets out the share ownership of the company following closing on a pro forma basis, which includes
a line item for 2,000,000 shares held by "PIPE Investors". Because it appears that no PIPE was obtained in connection with
the closing, please explain the inclusion of this line item.

In response to the Staff’s comment,
the Company has revised the disclosure on page 69 of Amendment No. 1.

General

 13. Revise your prospectus to disclose the price that each selling
shareholder paid for the shares being registered for resale. Highlight any differences in the current trading price, the prices at which
the other selling shareholders acquired their shares and warrants, and the price that the public shareholders paid to acquire their shares
and warrants. Disclose that while the other selling shareholders may experience a positive rate of return based on the current trading
price, the public shareholders may not experience a similar rate of return on the shares they purchased due to differences in the purchase
prices and the current trading price. Please also disclose on an individual basis the potential profit the selling shareholders will
earn based on the current trading price. Lastly, please include appropriate risk factor disclosure regarding each of these points.

In response to the Staff’s comment,
the Company has revised the disclosure on the cover page, page 39 and pages 48 - 53 of Amendment No. 1.

* * *

We thank the Staff for its
review of this response. Should you have any questions or require any additional information, please do not hesitate to contact our legal
counsel, Benjamin Reichel, Esq. of Ellenoff Grossman & Schole LLP, at breichel@egsllp.com or by telephone at (212) 370-1300.

    Very truly yours,

    Pysence Biomedical Ltd.

    By:
    /s/ Neil Maresky

    Name:
    Neil Maresky

    Title:
    Chief Executive Officer

    cc:
    Ellenoff Grossman & Schole LLP

      4